• Pure. Human.™

    Cor.4U® iPSC Derived
    Human Cardiomyocytes

    For CV drug discovery, cardiac safety testing and more   >> More Information <<

  • 15-19 November 2014, Washington DC USA

    Neuroscience 2014

                                 Launch of Human iPSC Neurons!

                     Visit us at Booth 2227        >> More Information <<

  • Pure. Human.™

    Peri.4UTM iPSC Derived
    Human Peripheral Neurons

    For pain drug discovery, botulinum toxin testing and more   >> More Information <<

  • In Vitro Disease Modeling with Human iPS Cells

    Cardiac Hypertrophy


    >> Read our article about using iPSC's in disease modeling <<
    This email address is being protected from spambots. You need JavaScript enabled to view it.

  • In Vitro Test for Developmental Toxicity

    uEST Test

    ECVAM-Validated | Highly Predictive

    >> More Information <<

Axiogenesis Overview

Axiogenesis AG is an international leader in the development and commercialization of in vitro models of healthy and diseased cell types and tissue.  Axiogenesis' technologies greatly improve the speed and confidence in discovering new therapies, and reduce attrition of failed compounds.

Since 2000, Axiogenesis has been in business to capture the promise of stem cells to revolutionize the fields of drug discovery & development and life sciences research.  Axiogenesis develops and commercializes stem cell-derived, in vitro differentiated cardiomyocytes, neurons and other cell types, as well as drug development assays and disease models, to help researchers discover cures.

Axiogenesis' flagship offering is the Cor.4U® human cardiomyocyte product, derived from induced pluripotent stem (iPS) cells, which is used in applications for single cell analysis to high-throughput screening (HTS) of pharmaceutical compounds.  Cor.4U® cardiomyocytes: Pure. Human.™

Expanding its human cell portfolio, Axiogenesis has launched human iPS cell-derived neuronal sub-types including dopaminergic neurons (Dopa.4U) and peripheral neurons (Peri.4U).

Axiogenesis was first-to-market with a pure stem cell-derived cardiomyocyte product, launching Cor.At® murine cardiomyocytes in 2008.  Cor.At® cardiomyocytes, along with murine stem cell-derived endothelial cells (Endo.4M) and smooth muscle cells (SMAC.4M), are distributed globally by Sigma Life Sciences.  Visit www.sigma.com/cardiac.

Applying Axiogenesis' pure cell types into market-driven solutions, Axiogenesis offers licensing of proprietary disease models, e.g. Hypertrophic Cardiomyopathy (HCM, also known as Cardiac Hypertrophy), for compound screening as well as value-added fee-for-service assays for in vitro toxicology, safety pharmacology and drug discovery.

Contact us to discuss how to use our discoveries to advance yours.


Follow us on LinkedIn
Follow us on Twitter
Subscribe to our Newsletter


Nattermannallee 1, Bldg S20
50829 Cologne, Germany

600 W Germantown Pike, Ste 110
Plymouth Meeting, PA 19462 USA



Phone (Main) +49 221 99 88 18-0
Phone (US) +1 844-511-6959
Fax + 49 221 99 88 18-10